Please login to the form below

Not currently logged in
Email:
Password:

VentiRx appoints James Kyle Bryan as chief medical officer

He has more than 20 years of experience in oncology

US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.

This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.

“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”

30th April 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics